[Cost- effectiveness analysis of pneumococcal vaccination in Iceland].
Pneumococcus is a common cause of disease among children and the elderly. With the emergence of resistant serotypes, antibiotic treatment is getting limited. Many countries have therefore introduced a vaccination program among children against the most common serotypes. The aim of this study was to analyse cost-effectiveness of adding a vaccination program against pneumococcus in Iceland.



A cost-effectiveness analysis was carried out from a societal perspective where the cost-effectiveness ratio ICER was estimated from the cost of each additional life and life year saved. The analyse was based on the year 2008 and all cost were calculated accordingly. The rate of 3% was used for net present-value calculation.



Annual societal cost due to pneumococcus in Iceland was estimated to be 718.146.252 ISK if children would be vaccinated but 565.026.552 ISK if they would not be vaccinated. The additional cost due to the vaccination program was therefore 153.119.700 ISK . The vaccination program could save 0,669 lives among children aged 0-4 years old and 21.11 life years. The cost was 228.878.476 ISK for each additional life saved and 7.253.420 ISK for each additional life year saved.



Given initial assumptions the results indicate that a vaccination programme against pneumococcal disease in Iceland would be cost effective.
Björnsdóttir
Margrét
M
gretab@live.com
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006291:Health Policy / Q000191:economics; D006801:Humans; D007055:Iceland; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D007231:Infant, Newborn; D032541:Mass Vaccination / Q000191:economics*; D018803:Models, Economic; D011008:Pneumococcal Infections / Q000191:economics* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*
D022242:Pneumococcal Vaccines